Delta Financial Group Inc. Has $4.46 Million Position in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Jul 18th, 2023

Delta Financial Group Inc. grew its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 1.6% in the 1st quarter, HoldingsChannel reports. The firm owned 28,774 shares of the company’s stock after buying an additional 467 shares during the quarter. Johnson & Johnson comprises approximately 1.8% of Delta Financial Group Inc.’s holdings, making the stock its 7th largest holding. Delta Financial Group Inc.’s holdings in Johnson & Johnson were worth $4,460,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of JNJ. DORCHESTER WEALTH MANAGEMENT Co raised its stake in shares of Johnson & Johnson by 8.6% during the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock worth $14,975,000 after acquiring an additional 5,327 shares in the last quarter. Cantor Fitzgerald Investment Advisor L.P raised its stake in shares of Johnson & Johnson by 88.9% during the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock worth $31,049,000 after acquiring an additional 82,429 shares in the last quarter. AMI Investment Management Inc. increased its stake in Johnson & Johnson by 8.8% during the 1st quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock valued at $3,244,000 after purchasing an additional 1,475 shares in the last quarter. Equitable Holdings Inc. increased its stake in Johnson & Johnson by 4.9% during the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock valued at $8,095,000 after purchasing an additional 2,119 shares in the last quarter. Finally, USS Investment Management Ltd increased its stake in Johnson & Johnson by 2.4% during the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after purchasing an additional 20,528 shares in the last quarter. Hedge funds and other institutional investors own 67.57% of the company’s stock.

Johnson & Johnson Stock Performance

JNJ opened at $159.06 on Tuesday. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.49. The company has a market cap of $413.35 billion, a price-to-earnings ratio of 33.28, a PEG ratio of 2.73 and a beta of 0.55. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $181.04. The firm’s fifty day simple moving average is $160.13 and its two-hundred day simple moving average is $161.64.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.51 by $0.17. The business had revenue of $24.75 billion for the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The company’s revenue was up 5.6% compared to the same quarter last year. During the same period last year, the firm posted $2.67 earnings per share. Equities analysts anticipate that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on JNJ shares. Citigroup started coverage on shares of Johnson & Johnson in a research note on Tuesday, May 30th. They set a “buy” rating and a $185.00 price target on the stock. UBS Group assumed coverage on shares of Johnson & Johnson in a research note on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price target on the stock. TheStreet lowered shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, May 19th. Credit Suisse Group increased their price objective on shares of Johnson & Johnson from $168.00 to $170.00 in a research note on Friday, May 5th. Finally, Raymond James cut their price objective on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 19th. Seven analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $169.77.

Insider Transactions at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the transaction, the executive vice president now directly owns 65,934 shares of the company’s stock, valued at $10,549,440. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.20% of the company’s stock.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Delta Financial Group Inc. Has $4.46 Million Position in Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson Stock Performance

Analyst Upgrades and Downgrades

Insider Transactions at Johnson & Johnson

Johnson & Johnson Profile

See Also

You might be interested in: